Sai-Hong Ignatius Ou

Sai-Hong Ignatius Ou

UNVERIFIED PROFILE

Are you Sai-Hong Ignatius Ou?   Register this Author

Register author
Sai-Hong Ignatius Ou

Sai-Hong Ignatius Ou

Publications by authors named "Sai-Hong Ignatius Ou"

Are you Sai-Hong Ignatius Ou?   Register this Author

100Publications

4307Reads

40Profile Views

The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.

Authors:
Umut Disel Russell Madison Kumar Abhishek Jon H Chung Sally E Trabucco Asli O Matos Garrett M Frampton Lee A Albacker Venkataprasanth Reddy Nuri Karadurmus Adam Benson Jennifer Webster Semra Paydas Ruben Cabanillas Chaitali Nangia M A Ozturk Sherri Z Millis Sumanta K Pal Breelyn Wilky Ethan S Sokol Laurie M Gay Salil Soman Shridar Ganesan Katherine Janeway Phil J Stephens Viola W Zhu Sai-Hong Ignatius Ou Christine M Lovly Mrinal Gounder Alexa B Schrock Jeffrey S Ross Vincent A Miller Samuel J Klempner Siraj M Ali

Oncologist 2020 Jan 11;25(1):e39-e47. Epub 2019 Oct 11.

Foundation Medicine, Inc., Cambridge, Massachusetts, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1634/theoncologist.2018-0528DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964135PMC
January 2020

The KRAS Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.

Authors:
Jill Hallin Lars D Engstrom Lauren Hargis Andrew Calinisan Ruth Aranda David M Briere Niranjan Sudhakar Vickie Bowcut Brian R Baer Joshua A Ballard Michael R Burkard Jay B Fell John P Fischer Guy P Vigers Yaohua Xue Sole Gatto Julio Fernandez-Banet Adam Pavlicek Karen Velastagui Richard C Chao Jeremy Barton Mariaelena Pierobon Elisa Baldelli Emanuel F Patricoin Douglas P Cassidy Matthew A Marx Igor I Rybkin Melissa L Johnson Sai-Hong Ignatius Ou Piro Lito Kyriakos P Papadopoulos Pasi A Jänne Peter Olson James G Christensen

Cancer Discov 2020 Jan 28;10(1):54-71. Epub 2019 Oct 28.

Mirati Therapeutics, Inc., San Diego, California.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/2159-8290.CD-19-1167DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954325PMC
January 2020

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.

Authors:
Sai-Hong Ignatius Ou Shirish M Gadgeel Fabrice Barlesi James Chih-Hsin Yang Luigi De Petris Dong-Wan Kim Ramaswamy Govindan Anne-Marie Dingemans Lucio Crino Hervé Léna Sanjay Popat Jin Seok Ahn Eric Dansin Emmanuel Mitry Barbara Müller Walter Bordogna Bogdana Balas Peter N Morcos Alice T Shaw

Lung Cancer 2020 Jan 14;139:22-27. Epub 2019 Oct 14.

Massachusetts General Hospital Cancer Center, Yawkey 7B, 32 Fruit Street, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2019.10.015DOI Listing
January 2020

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.

Authors:
Alexander Drilon Jeffrey W Clark Jared Weiss Sai-Hong Ignatius Ou D Ross Camidge Benjamin J Solomon Gregory A Otterson Liza C Villaruz Gregory J Riely Rebecca S Heist Mark M Awad Geoffrey I Shapiro Miyako Satouchi Toyoaki Hida Hidetoshi Hayashi Danielle A Murphy Sherry C Wang Sherry Li Tiziana Usari Keith D Wilner Paul K Paik

Nat Med 2020 Jan 13;26(1):47-51. Epub 2020 Jan 13.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1038/s41591-019-0716-8DOI Listing
January 2020

Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-231].

Authors:
Sai-Hong Ignatius Ou Jean Cui Alexa B Schrock Michael E Goldberg Viola W Zhu Lee Albacker Philip J Stephens Vincent A Miller Siraj M Ali

Lung Cancer 2019 Dec 22;138:141. Epub 2019 Aug 22.

Foundation Medicine Inc, Cambridge, MA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2019.08.013DOI Listing
December 2019

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.

Authors:
Alice T Shaw Benjamin J Solomon Rita Chiari Gregory J Riely Benjamin Besse Ross A Soo Steven Kao Chia-Chi Lin Todd M Bauer Jill S Clancy Holger Thurm Jean-Francois Martini Gerson Peltz Antonello Abbattista Sherry Li Sai-Hong Ignatius Ou

Lancet Oncol 2019 Dec 25;20(12):1691-1701. Epub 2019 Oct 25.

University of California Irvine, Irvine, CA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/S1470-2045(19)30655-2DOI Listing
December 2019

ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials.

Authors:
Johannes Noé Alex Lovejoy Sai-Hong Ignatius Ou Stephanie J Yaung Walter Bordogna Daniel M Klass Craig A Cummings Alice T Shaw

J Thorac Oncol 2019 Nov 9. Epub 2019 Nov 9.

Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2019.10.015DOI Listing
November 2019

Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.

Authors:
Viola W Zhu Samuel J Klempner Sai-Hong Ignatius Ou

Trends Cancer 2019 Nov 29;5(11):677-692. Epub 2019 Oct 29.

University of California Irvine School of Medicine, Department of Medicine, Division of Hematology/Oncology, Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.trecan.2019.09.008DOI Listing
November 2019

Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors.

Authors:
Jessica J Lin Adam J Schoenfeld Viola W Zhu Beow Y Yeap Emily Chin Marguerite Rooney Andrew J Plodkowski Subba R Digumarthy Ibiayi Dagogo-Jack Justin F Gainor Sai-Hong Ignatius Ou Gregory J Riely Alice T Shaw

J Thorac Oncol 2019 Oct 26. Epub 2019 Oct 26.

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2019.10.014DOI Listing
October 2019

Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.

Authors:
Hui Xia Xingyang Xue Huaxin Ding Qiuxiang Ou Xue Wu Misako Nagasaka Yang W Shao Xingsheng Hu Sai-Hong Ignatius Ou

Clin Lung Cancer 2019 Sep 26. Epub 2019 Sep 26.

Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange, CA. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.cllc.2019.09.004DOI Listing
September 2019

Neuregulin 1 Fusion-Positive NSCLC.

Authors:
Misako Nagasaka Sai-Hong Ignatius Ou

J Thorac Oncol 2019 08 22;14(8):1354-1359. Epub 2019 May 22.

Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, California. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2019.05.015DOI Listing
August 2019

Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.

Authors:
Alice T Shaw Benjamin J Solomon Benjamin Besse Todd M Bauer Chia-Chi Lin Ross A Soo Gregory J Riely Sai-Hong Ignatius Ou Jill S Clancy Sherry Li Antonello Abbattista Holger Thurm Miyako Satouchi D Ross Camidge Steven Kao Rita Chiari Shirish M Gadgeel Enriqueta Felip Jean-François Martini

J Clin Oncol 2019 Jun 20;37(16):1370-1379. Epub 2019 Mar 20.

10 Pfizer Oncology, La Jolla, CA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.18.02236DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544460PMC
June 2019

CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome.

Authors:
Sai-Hong Ignatius Ou Viola W Zhu

Lung Cancer 2019 04 22;130:201-207. Epub 2019 Feb 22.

University of California Irvine School of Medicine, Department of Medicine, Division of Hematology-Oncology, Chao Family Comprehensive Cancer Center, Orange County, CA, 92868, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2019.02.025DOI Listing
April 2019

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with -mutant non-small cell lung cancer and emergent amplification.

Authors:
Viola W Zhu Alexa B Schrock Siraj M Ali Sai-Hong Ignatius Ou

Lung Cancer (Auckl) 2019 12;10:21-26. Epub 2019 Mar 12.

Chao Family Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA,

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.2147/LCTT.S190403DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419586PMC
March 2019

Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.

Authors:
Alexa B Schrock Allison Welsh Jon H Chung Dean Pavlick Eric H Bernicker Benjamin C Creelan Brady Forcier Jeffrey S Ross Philip J Stephens Siraj M Ali Ibiayi Dagogo-Jack Alice T Shaw Tianhong Li Sai-Hong Ignatius Ou Vincent A Miller

J Thorac Oncol 2019 02 24;14(2):255-264. Epub 2018 Oct 24.

Foundation Medicine, Inc., Cambridge, Massachusetts.

View Article

Download full-text PDF

 Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183320
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.10.008DOI Listing
February 2019

Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK-Positive Non-Small-Cell Lung Cancer: Histologic Analysis.

Authors:
Viola W Zhu Yuxin Lu Sai-Hong Ignatius Ou

Clin Lung Cancer 2019 01 21;20(1):e77-e80. Epub 2018 Sep 21.

Division of Hematology/Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange, CA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.cllc.2018.09.006DOI Listing
January 2019

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

Authors:
Benjamin J Solomon Benjamin Besse Todd M Bauer Enriqueta Felip Ross A Soo D Ross Camidge Rita Chiari Alessandra Bearz Chia-Chi Lin Shirish M Gadgeel Gregory J Riely Eng Huat Tan Takashi Seto Leonard P James Jill S Clancy Antonello Abbattista Jean-François Martini Joseph Chen Gerson Peltz Holger Thurm Sai-Hong Ignatius Ou Alice T Shaw

Lancet Oncol 2018 12 6;19(12):1654-1667. Epub 2018 Nov 6.

Massachusetts General Hospital, Boston, MA, USA.

View Article

Download full-text PDF

 Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183064
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30649-1DOI Listing
December 2018

Dramatic response to alectinib in a lung cancer patient with a novel fusion and an acquired ALK T1151K mutation.

Authors:
Viola W Zhu Alexa B Schrock Thangavijayan Bosemani Bryan S Benn Siraj M Ali Sai-Hong Ignatius Ou

Lung Cancer (Auckl) 2018 8;9:111-116. Epub 2018 Nov 8.

Chao Family Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA,

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.2147/LCTT.S186804DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234987PMC
November 2018

Pacific Rim redux: lorlatinib, the ultimate Jaeger?

Authors:
Viola W Zhu Sai-Hong Ignatius Ou

Ann Transl Med 2018 Nov;6(Suppl 1):S40

Chao Family Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA.

View Article

Download full-text PDF

 Source
http://atm.amegroups.com/article/view/21777/21832
Publisher Site
http://dx.doi.org/10.21037/atm.2018.09.49DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291554PMC
November 2018

Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.

Authors:
Jessica J Lin Viola W Zhu Adam J Schoenfeld Beow Y Yeap Ashish Saxena Lorin A Ferris Ibiayi Dagogo-Jack Anna F Farago Angela Taber Anne Traynor Smitha Menon Justin F Gainor Jochen K Lennerz Andrew J Plodkowski Subba R Digumarthy Sai-Hong Ignatius Ou Alice T Shaw Gregory J Riely

J Thorac Oncol 2018 10 20;13(10):1530-1538. Epub 2018 Jun 20.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2018.06.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341982PMC
October 2018

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC.

Authors:
Jonathan W Riess David R Gandara Garrett M Frampton Russell Madison Nir Peled Jose A Bufill Grace K Dy Sai-Hong Ignatius Ou Philip J Stephens John D McPherson Primo N Lara Rebekah A Burich Jeffrey S Ross Vincent A Miller Siraj M Ali Philip C Mack Alexa B Schrock

J Thorac Oncol 2018 10 5;13(10):1560-1568. Epub 2018 Jul 5.

Foundation Medicine, Cambridge, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2018.06.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764748PMC
October 2018

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.

Authors:
Alexander Drilon Sai-Hong Ignatius Ou Byoung Chul Cho Dong-Wan Kim Jeeyun Lee Jessica J Lin Viola W Zhu Myung-Ju Ahn D Ross Camidge Judy Nguyen Dayong Zhai Wei Deng Zhongdong Huang Evan Rogers Juliet Liu Jeff Whitten John K Lim Shanna Stopatschinskaja David M Hyman Robert C Doebele J Jean Cui Alice T Shaw

Cancer Discov 2018 10 9;8(10):1227-1236. Epub 2018 Aug 9.

Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

 Source
http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-18-0484DOI Listing
October 2018

Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutation.

Authors:
Samuel J Klempner Kyle Gowen Thomas K Lee Viola W Zhu Alexa B Schrock Vincent A Miller Siraj M Ali Sai-Hong Ignatius Ou

Lung Cancer 2018 10 31;124:86-89. Epub 2018 Jul 31.

Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, CA 92868, USA; Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

 Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002183050
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2018.07.043DOI Listing
October 2018

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.

Authors:
D Ross Camidge Dong-Wan Kim Marcello Tiseo Corey J Langer Myung-Ju Ahn Alice T Shaw Rudolf M Huber Maximilian J Hochmair Dae Ho Lee Lyudmila A Bazhenova Kathryn A Gold Sai-Hong Ignatius Ou Howard L West William Reichmann Jeff Haney Tim Clackson David Kerstein Scott N Gettinger

J Clin Oncol 2018 09 16;36(26):2693-2701. Epub 2018 May 16.

D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Dae Ho Lee, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Corey J. Langer, University of Pennsylvania, Philadelphia, PA; Alice T. Shaw, Massachusetts General Hospital, Boston; William Reichmann, Jeff Haney, Tim Clackson, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; Rudolf M. Huber, University Hospital of Munich, Munich, Germany; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Lyudmila A. Bazhenova and Kathryn A. Gold, University of California San Diego Moores Cancer Center, La Jolla; Sai-Hong Ignatius Ou, University of California Irvine School of Medicine, Irvine, CA; Howard L. West, Swedish Cancer Institute, Seattle, WA; and Scott N. Gettinger, Yale Cancer Center, New Haven, CT.

View Article

Download full-text PDF

 Source
http://ascopubs.org/doi/10.1200/JCO.2017.77.5841
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.77.5841DOI Listing
September 2018

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.

Authors:
Alexa B Schrock Viola W Zhu Wen-Son Hsieh Russell Madison Benjamin Creelan Jeffrey Silberberg Dan Costin Anjali Bharne Ioana Bonta Thangavijayan Bosemani Petros Nikolinakos Jeffrey S Ross Vincent A Miller Siraj M Ali Samuel J Klempner Sai-Hong Ignatius Ou

J Thorac Oncol 2018 09 5;13(9):1312-1323. Epub 2018 Jun 5.

University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, California. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2018.05.027DOI Listing
September 2018

Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient.

Authors:
Xinghao Ai Xiaomin Niu Lianpeng Chang Rongrong Chen Sai-Hong Ignatius Ou Shun Lu

Lung Cancer 2018 09 6;123:83-86. Epub 2018 Jul 6.

Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200032, China. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2018.07.004DOI Listing
September 2018

Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.

Authors:
James H Suh Alexa B Schrock Adrienne Johnson Doron Lipson Laurie M Gay Shakti Ramkissoon Jo-Anne Vergilio Julia A Elvin Abdur Shakir Peter Ruehlman Karen L Reckamp Sai-Hong Ignatius Ou Jeffrey S Ross Philip J Stephens Vincent A Miller Siraj M Ali

Oncologist 2018 07 14;23(7):776-781. Epub 2018 Mar 14.

Foundation Medicine Inc., Cambridge, Massachusetts, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1634/theoncologist.2017-0493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058345PMC
July 2018

Precision Targeted Therapy with BLU-667 for -Driven Cancers.

Authors:
Vivek Subbiah Justin F Gainor Rami Rahal Jason D Brubaker Joseph L Kim Michelle Maynard Wei Hu Qiongfang Cao Michael P Sheets Douglas Wilson Kevin J Wilson Lucian DiPietro Paul Fleming Michael Palmer Mimi I Hu Lori Wirth Marcia S Brose Sai-Hong Ignatius Ou Matthew Taylor Elena Garralda Stephen Miller Beni Wolf Christoph Lengauer Timothy Guzi Erica K Evans

Cancer Discov 2018 07 15;8(7):836-849. Epub 2018 Apr 15.

Blueprint Medicines Corporation, Cambridge, Massachusetts.

View Article

Download full-text PDF

 Source
http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-18-0338DOI Listing
July 2018

Patient-reported outcomes in a phase II, North American study of alectinib in patients with -positive, crizotinib-resistant, non-small cell lung cancer.

Authors:
Sai-Hong Ignatius Ou Mark A Socinski Shirish Gadgeel Leena Gandhi Howard West Alberto Alejandro Chiappori Victor Cohen Gregory J Riely Vlatka Smoljanovic Walter Bordogna Elaine Wright Kendra Debusk Ali Zeaiter Alice T Shaw

ESMO Open 2018 12;3(5):e000364. Epub 2018 Jul 12.

Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1136/esmoopen-2018-000364DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045737PMC
July 2018

Liquid Biopsy to Identify Actionable Genomic Alterations.

Authors:
Sai-Hong Ignatius Ou Misako Nagasaka Viola W Zhu

Am Soc Clin Oncol Educ Book 2018 May;38:978-997

From Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; Karmanos Cancer Center, Wayne State University, Detroit, MI; Hematology/Oncology Section, Veterans Affairs Long Beach Healthcare System, Long Beach, CA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/EDBK_199765DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865813PMC
May 2018

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

Authors:
Jessica J Lin Viola W Zhu Satoshi Yoda Beow Y Yeap Alexa B Schrock Ibiayi Dagogo-Jack Nicholas A Jessop Ginger Y Jiang Long P Le Kyle Gowen Philip J Stephens Jeffrey S Ross Siraj M Ali Vincent A Miller Melissa L Johnson Christine M Lovly Aaron N Hata Justin F Gainor Anthony J Iafrate Alice T Shaw Sai-Hong Ignatius Ou

J Clin Oncol 2018 04 26;36(12):1199-1206. Epub 2018 Jan 26.

Jessica J. Lin, Satoshi Yoda, Beow Y. Yeap, Ibiayi Dagogo-Jack, Nicholas A. Jessop, Ginger Y. Jiang, Long P. Le, Aaron N. Hata, Justin F. Gainor, Anthony J. Iafrate, and Alice T. Shaw, Massachusetts General Hospital, Boston; Alexa B. Schrock, Kyle Gowen, Philip J. Stephens, Jeffrey S. Ross, Siraj M. Ali, and Vincent A. Miller, Foundation Medicine, Cambridge, MA; Viola W. Zhu and Sai-Hong Ignatius Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; Melissa L. Johnson, Sarah Cannon Research Institute; and Christine M. Lovly, Vanderbilt-Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2017.76.2294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903999PMC
April 2018

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.

Authors:
Niki Karachaliou Imane Chaib Andres Felipe Cardona Jordi Berenguer Jillian Wilhelmina Paulina Bracht Jie Yang Xueting Cai Zhigang Wang Chunping Hu Ana Drozdowskyj Carles Codony Servat Jordi Codony Servat Masaoki Ito Ilaria Attili Erika Aldeguer Ana Gimenez Capitan July Rodriguez Leonardo Rojas Santiago Viteri Miguel Angel Molina-Vila Sai-Hong Ignatius Ou Morihito Okada Tony S Mok Trever G Bivona Mayumi Ono Jean Cui Santiago Ramón Y Cajal Alex Frias Peng Cao Rafael Rosell

EBioMedicine 2018 03 5;29:112-127. Epub 2018 Feb 5.

Pangaea Oncology, Laboratory of Molecular Biology, Coyote Reserach Group, Quirón-Dexeus University Institute, Barcelona, Spain; Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain; Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.ebiom.2018.02.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925453PMC
March 2018

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.

Authors:
Shirish Gadgeel Alice T Shaw Fabrice Barlesi Lucio Crinò James Chih-Hsin Yang Anne-Marie C Dingemans Dong-Wan Kim Filippo de Marinis Mathias Schulz Shiyao Liu Ravindra Gupta Ahmed Kotb Sai-Hong Ignatius Ou

Br J Cancer 2018 01 16;118(1):38-42. Epub 2017 Nov 16.

Department of Medicine, University of California Irvine School of Medicine, 1001 Health Sciences Road, Irvine, CA 92617, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1038/bjc.2017.395DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765233PMC
January 2018

-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature.

Authors:
Samuel J Klempner Pareen Mehta Alexa B Schrock Siraj M Ali Sai-Hong Ignatius Ou

Lung Cancer (Auckl) 2017 6;8:241-247. Epub 2017 Dec 6.

Department of Medicine-Hematology/Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA, USA.

View Article

Download full-text PDF

 Source
https://www.dovepress.com/cis-oriented-solvent-front-egfr-g7
Publisher Site
http://dx.doi.org/10.2147/LCTT.S147129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723122PMC
December 2017

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.

Authors:
James Chih-Hsin Yang Sai-Hong Ignatius Ou Luigi De Petris Shirish Gadgeel Leena Gandhi Dong-Wan Kim Fabrice Barlesi Ramaswamy Govindan Anne-Marie C Dingemans Lucio Crino Herve Lena Sanjay Popat Jin Seok Ahn Eric Dansin Sophie Golding Walter Bordogna Bogdana Balas Peter N Morcos Ali Zeaiter Alice T Shaw

J Thorac Oncol 2017 10 6;12(10):1552-1560. Epub 2017 Jul 6.

Massachusetts General Hospital Cancer Centre, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2017.06.070DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886236PMC
October 2017

ASCEND-5: too little too late?

Authors:
Fengying Wu Sai-Hong Ignatius Ou

J Thorac Dis 2017 Oct;9(10):3477-3479

Department of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.21037/jtd.2017.08.147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723760PMC
October 2017

Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry.

Authors:
Ross A Soo Akihito Kubo Masahiko Ando Tomoya Kawaguchi Myung-Ju Ahn Sai-Hong Ignatius Ou

Clin Lung Cancer 2017 09 19;18(5):535-542. Epub 2017 Jan 19.

Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.cllc.2017.01.005DOI Listing
September 2017

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.

Authors:
Leena Gandhi Sai-Hong Ignatius Ou Alice T Shaw Fabrice Barlesi Anne-Marie C Dingemans Dong-Wan Kim D Ross Camidge Brett G M Hughes James C-H Yang Javier de Castro Lucio Crino Hervé Léna Pascal Do Sophie Golding Walter Bordogna Ali Zeaiter Ahmed Kotb Shirish Gadgeel

Eur J Cancer 2017 09 10;82:27-33. Epub 2017 Jul 10.

Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.

View Article

Download full-text PDF

 Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049173097
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2017.05.019DOI Listing
September 2017

Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.

Authors:
Sai-Hong Ignatius Ou Leora Horn Marcelo Cruz Davood Vafai Christine M Lovly Allison Spradlin Michael J Williamson Ibiayi Dagogo-Jack Adrienne Johnson Vincent A Miller Shirish Gadgeel Siraj M Ali Alexa B Schrock

Lung Cancer 2017 09 11;111:61-64. Epub 2017 Jul 11.

Foundation Medicine, Inc., Cambridge, MA, United States.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2017.07.006DOI Listing
September 2017

Further Advances in the Management of Anaplastic Lymphoma Kinase-Mutated Non-Small-Cell Lung Cancer.

Authors:
Sai-Hong Ignatius Ou

J Clin Oncol 2017 08 11;35(22):2463-2466. Epub 2017 May 11.

Sai-Hong Ignatius Ou, University of California Irvine School of Medicine, Orange, CA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2017.73.1323DOI Listing
August 2017

Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.

Authors:
Viola W Zhu J Jean Cui Maria Fernandez-Rocha Alexa B Schrock Siraj M Ali Sai-Hong Ignatius Ou

Lung Cancer 2017 08 22;110:32-34. Epub 2017 May 22.

Foundation Medicine, Inc., Cambridge, MA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2017.05.018DOI Listing
August 2017

METex14-Positive NSCLC: Time to Take the Therapy to the Target to Aim for a Cure?

Authors:
Viola W Zhu Sai-Hong Ignatius Ou

J Thorac Oncol 2017 08;12(8):1180-1182

Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, California. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2017.06.009DOI Listing
August 2017

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.

Authors:
Alexa B Schrock Shuyu D Li Garrett M Frampton James Suh Eduardo Braun Ranee Mehra Steven C Buck Jose A Bufill Nir Peled Nagla Abdel Karim K Cynthia Hsieh Manuel Doria James Knost Rong Chen Sai-Hong Ignatius Ou Jeffrey S Ross Philip J Stephens Paul Fishkin Vincent A Miller Siraj M Ali Balazs Halmos Jane J Liu

J Thorac Oncol 2017 06 16;12(6):932-942. Epub 2017 Mar 16.

Illinois CancerCare, Peoria, Illinois.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2017.03.005DOI Listing
June 2017

Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.

Authors:
Sai-Hong Ignatius Ou Jean Cui Alexa B Schrock Michael E Goldberg Viola W Zhu Lee Albacker Philip J Stephens Vincent A Miller Siraj M Ali

Lung Cancer 2017 06 12;108:228-231. Epub 2017 Apr 12.

Foundation Medicine Inc, Cambridge, MA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2017.04.003DOI Listing
June 2017

Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.

Authors:
Justin M Allen Alexa B Schrock Rachel L Erlich Vincent A Miller Philip J Stephens Jeffrey S Ross Sai-Hong Ignatius Ou Siraj M Ali Davood Vafai

Clin Lung Cancer 2017 05 22;18(3):e219-e222. Epub 2016 Dec 22.

Eisenhower Lucy Curci Cancer Center, Rancho Mirage, CA.

View Article

Download full-text PDF

 Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304163038
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2016.12.006DOI Listing
May 2017

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Authors:
Oliver Gautschi Julie Milia Thomas Filleron Juergen Wolf David P Carbone Dwight Owen Ross Camidge Vignhesh Narayanan Robert C Doebele Benjamin Besse Jordi Remon-Masip Pasi A Janne Mark M Awad Nir Peled Chul-Cho Byoung Daniel D Karp Michael Van Den Heuvel Heather A Wakelee Joel W Neal Tony S K Mok James C H Yang Sai-Hong Ignatius Ou Georg Pall Patrizia Froesch Gérard Zalcman David R Gandara Jonathan W Riess Vamsidhar Velcheti Kristin Zeidler Joachim Diebold Martin Früh Sebastian Michels Isabelle Monnet Sanjay Popat Rafael Rosell Niki Karachaliou Sacha I Rothschild Jin-Yuan Shih Arne Warth Thomas Muley Florian Cabillic Julien Mazières Alexander Drilon

J Clin Oncol 2017 May 13;35(13):1403-1410. Epub 2017 Mar 13.

Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2016.70.9352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559893PMC
May 2017

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Authors:
Alexander Drilon Salvatore Siena Sai-Hong Ignatius Ou Manish Patel Myung Ju Ahn Jeeyun Lee Todd M Bauer Anna F Farago Jennifer J Wheler Stephen V Liu Robert Doebele Laura Giannetta Giulio Cerea Giovanna Marrapese Michele Schirru Alessio Amatu Katia Bencardino Laura Palmeri Andrea Sartore-Bianchi Angelo Vanzulli Sara Cresta Silvia Damian Matteo Duca Elena Ardini Gang Li Jason Christiansen Karey Kowalski Ann D Johnson Rupal Patel David Luo Edna Chow-Maneval Zachary Hornby Pratik S Multani Alice T Shaw Filippo G De Braud

Cancer Discov 2017 04 9;7(4):400-409. Epub 2017 Feb 9.

Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milan, Italy.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/2159-8290.CD-16-1237DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380583PMC
April 2017

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

Authors:
Sai-Hong Ignatius Ou Thomas K Lee Lauren Young Maria Y Fernandez-Rocha Dean Pavlick Alexa B Schrock Viola W Zhu Jeffrey Milliken Siraj M Ali Barbara J Gitlitz

Lung Cancer 2017 04 9;106:110-114. Epub 2017 Feb 9.

Department of Medicine, Division of Hematology-Oncology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2017.02.005DOI Listing
April 2017

HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.

Authors:
Sai-Hong Ignatius Ou Alexa B Schrock Eduard V Bocharov Samuel J Klempner Carolina Kawamura Haddad Gary Steinecker Melissa Johnson Barbara J Gitlitz Jon Chung Paulo V Campregher Jeffrey S Ross Philip J Stephens Vincent A Miller James H Suh Siraj M Ali Vamsidhar Velcheti

J Thorac Oncol 2017 03 27;12(3):446-457. Epub 2016 Nov 27.

Cleveland Clinic, Cleveland Clinic Main Campus, Cleveland, Ohio.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2016.11.2224DOI Listing
March 2017

Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.

Authors:
Pierre Vanden Borre Alexa B Schrock Peter M Anderson John C Morris Andreas M Heilmann Oliver Holmes Kai Wang Adrienne Johnson Steven G Waguespack Sai-Hong Ignatius Ou Saad Khan Kar-Ming Fung Philip J Stephens Rachel L Erlich Vincent A Miller Jeffrey S Ross Siraj M Ali

Oncologist 2017 03 16;22(3):255-263. Epub 2017 Feb 16.

Foundation Medicine, Cambridge, Massachusetts, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1634/theoncologist.2016-0279DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344643PMC
March 2017

Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.

Authors:
Benjamin A Weinberg Kyle Gowen Thomas K Lee Sai-Hong Ignatius Ou Robert Bristow Lauren Krill M Isabel Almira-Suarez Siraj M Ali Vincent A Miller Stephen V Liu Samuel J Klempner

Oncologist 2017 02 13;22(2):152-157. Epub 2017 Feb 13.

The Angeles Clinic and Research Institute, Los Angeles, California, USA

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1634/theoncologist.2015-0511DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330711PMC
February 2017

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.

Authors:
Rafael Caparica Cheng Tzu Yen Renata Coudry Sai-Hong Ignatius Ou Marileila Varella-Garcia D Ross Camidge Gilberto de Castro

J Thorac Oncol 2017 01 21;12(1):141-144. Epub 2016 Sep 21.

Clinical Oncology, Cancer Institute of the State of São Paulo, School of Medicine, University of São Paulo, São Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2016.09.116DOI Listing
January 2017

Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases.

Authors:
Samuel J Klempner Ali Borghei Behrooz Hakimian Siraj M Ali Sai-Hong Ignatius Ou

J Thorac Oncol 2017 01 28;12(1):152-156. Epub 2016 Sep 28.

Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, California.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2016.09.127DOI Listing
January 2017

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.

Authors:
Sai-Hong Ignatius Ou Ramaswamy Govindan Keith D Eaton Gregory A Otterson Martin E Gutierrez Alain C Mita Athanassios Argiris Nicoletta M Brega Tiziana Usari Weiwei Tan Steffan N Ho Francisco Robert

J Thorac Oncol 2017 01 30;12(1):145-151. Epub 2016 Sep 30.

Birmingham Veterans Administration Hospital, Birmingham, Alabama; University of Alabama-Birmingham Comprehensive Cancer Center, Birmingham, Alabama.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2016.09.131DOI Listing
January 2017

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.

Authors:
Sai-Hong Ignatius Ou Lauren Young Alexa B Schrock Adrienne Johnson Samuel J Klempner Viola W Zhu Vincent A Miller Siraj M Ali

J Thorac Oncol 2017 01 22;12(1):137-140. Epub 2016 Sep 22.

Foundation Medicine, Inc., Cambridge, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2016.09.119DOI Listing
January 2017

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Authors:
Alexander Drilon Federico Cappuzzo Sai-Hong Ignatius Ou D Ross Camidge

J Thorac Oncol 2017 01 26;12(1):15-26. Epub 2016 Oct 26.

University of Colorado Cancer Center, Aurora, Colorado.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2016.10.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603268PMC
January 2017

The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.

Authors:
Thanyanan Reungwetwattana Ying Liang Viola Zhu Sai-Hong Ignatius Ou

Lung Cancer 2017 01 15;103:27-37. Epub 2016 Nov 15.

Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange County, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2016.11.011DOI Listing
January 2017

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

Authors:
Shirish M Gadgeel Alice T Shaw Ramaswamy Govindan Leena Gandhi Mark A Socinski D Ross Camidge Luigi De Petris Dong-Wan Kim Alberto Chiappori Denis L Moro-Sibilot Michael Duruisseaux Lucio Crino Tommaso De Pas Eric Dansin Antje Tessmer James Chih-Hsin Yang Ji-Youn Han Walter Bordogna Sophie Golding Ali Zeaiter Sai-Hong Ignatius Ou

J Clin Oncol 2016 12 31;34(34):4079-4085. Epub 2016 Oct 31.

Shirish M. Gadgeel, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Alice T. Shaw, Massachusetts General Hospital; Leena Gandhi, Dana-Farber Cancer Institute, Boston, MA; Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; D. Ross Camidge, University of Colorado Cancer Center, Denver, CO; Alberto Chiappori, Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Sai-Hong Ignatius Ou, University of California at Irvine, Orange, CA; Luigi De Petris, Karolinska Institutet, Stockholm, Sweden; Dong-Wan Kim, Seoul National University Hospital, Seoul; Ji-Youn Han, Lung Cancer Centre, National Cancer Centre, Goyang, South Korea; Denis L. Moro-Sibilot, Service de Pneumologie; Michael Duruisseaux, Centre Hospitalier Universitaire de Grenoble, Grenoble; Eric Dansin, Centre Oscar Lambret, Lille, France; Lucio Crino, Santa Maria della Misericordia Hospital, Perugia; Tommaso De Pas, European Institute of Oncology, Milan, Italy; Antje Tessmer, Evangelische Lungenklinik Berlin, Berlin, Germany; James Chih-Hsin Yang, Graduate Institute of Oncology and Cancer Research Centre, National Taiwan University, Taipei, Taiwan; and Walter Bordogna, Sophie Golding, and Ali Zeaiter, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2016.68.4639DOI Listing
December 2016

ASCEND-2: a canary in a coal mine for descending to second-line treatment for -rearranged non-small cell lung cancer.

Authors:
Viola W Zhu Sai-Hong Ignatius Ou

Transl Lung Cancer Res 2016 Dec;5(6):660-664

Division of Hematology/Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine School of Medicine, Orange, CA 92868, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.21037/tlcr.2016.12.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5233869PMC
December 2016

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.

Authors:
Alexa B Schrock Garrett M Frampton James Suh Zachary R Chalmers Mark Rosenzweig Rachel L Erlich Balazs Halmos Jonathan Goldman Patrick Forde Kurt Leuenberger Nir Peled Gregory P Kalemkerian Jeffrey S Ross Philip J Stephens Vincent A Miller Siraj M Ali Sai-Hong Ignatius Ou

J Thorac Oncol 2016 09 22;11(9):1493-502. Epub 2016 Jun 22.

Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2016.06.004DOI Listing
September 2016

High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.

Authors:
Sai-Hong Ignatius Ou Nikita Agarwal Siraj M Ali

Lung Cancer 2016 08 25;98:59-61. Epub 2016 May 25.

Foundation Medicine, Inc., Cambridge, MA 02141, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2016.05.015DOI Listing
August 2016

Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?

Authors:
Sai-Hong Ignatius Ou Ross A Soo

Drug Des Devel Ther 2015 15;9:5641-53. Epub 2015 Oct 15.

National University Health System and Cancer Science Institute of Singapore, Singapore.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.2147/DDDT.S52787DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610796PMC
July 2016

Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing.

Authors:
Alexa B Schrock Garrett M Frampton Dana Herndon Joel R Greenbowe Kai Wang Doron Lipson Roman Yelensky Zachary R Chalmers Juliann Chmielecki Julia A Elvin Mira Wollner Addie Dvir Lior Soussan -Gutman Rodolfo Bordoni Nir Peled Fadi Braiteh Luis Raez Rachel Erlich Sai-Hong Ignatius Ou Mohamed Mohamed Jeffrey S Ross Philip J Stephens Siraj M Ali Vincent A Miller

Clin Cancer Res 2016 07 1;22(13):3281-5. Epub 2016 Mar 1.

Foundation Medicine Inc., Cambridge, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1668DOI Listing
July 2016

TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.

Authors:
Viola Weijia Zhu Daya Upadhyay Alexa B Schrock Kyle Gowen Siraj M Ali Sai-Hong Ignatius Ou

Lung Cancer 2016 07 22;97:48-50. Epub 2016 Apr 22.

Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California, Irvine School of Medicine, Orange, CA 92868, United States.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2016.04.013DOI Listing
July 2016

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.

Authors:
Samuel J Klempner Bruce Gershenhorn Phu Tran Thomas K Lee Mark G Erlander Kyle Gowen Alexa B Schrock Deborah Morosini Jeffrey S Ross Vincent A Miller Philip J Stephens Sai-Hong Ignatius Ou Siraj M Ali

Cancer Discov 2016 06 5;6(6):594-600. Epub 2016 Apr 5.

Foundation Medicine, Inc., Cambridge, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/2159-8290.CD-15-1192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008024PMC
June 2016

Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.

Authors:
Sai-Hong Ignatius Ou Michael Weitz John R Jalas Daniel F Kelly Vanessa Wong Michele C Azada Oliver Quines Samuel J Klempner

Lung Cancer 2016 06 26;96:15-8. Epub 2016 Mar 26.

Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, CA 92868, United States; Chao Family Comprehensive Cancer Center, Orange, CA 92868, United States.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2016.03.008DOI Listing
June 2016

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

Authors:
Siraj M Ali Thomas Hensing Alexa B Schrock Justin Allen Eric Sanford Kyle Gowen Atul Kulkarni Jie He James H Suh Doron Lipson Julia A Elvin Roman Yelensky Zachary Chalmers Juliann Chmielecki Nir Peled Samuel J Klempner Kashif Firozvi Garrett M Frampton Julian R Molina Smitha Menon Julie R Brahmer Heber MacMahon Jan Nowak Sai-Hong Ignatius Ou Marjorie Zauderer Marc Ladanyi Maureen Zakowski Neil Fischbach Jeffrey S Ross Phil J Stephens Vincent A Miller Heather Wakelee Shridar Ganesan Ravi Salgia

Oncologist 2016 06 31;21(6):762-70. Epub 2016 May 31.

Department of Medicine, The University of Chicago, Chicago, Illinois, USA

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1634/theoncologist.2015-0497DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912370PMC
June 2016

Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.

Authors:
Sai-Hong Ignatius Ou Keisuke Shirai

Adv Exp Med Biol 2016 ;893:179-187

MUSC Hollings Cancer Center, Department of Medicine, Division of Hematology-Oncology, Medical University of South Carolina College of Medicine, Charleston, SC, 29403, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/978-3-319-24223-1_9DOI Listing
May 2016

Scientific Advances in Lung Cancer 2015.

Authors:
Anne S Tsao Giorgio V Scagliotti Paul A Bunn David P Carbone Graham W Warren Chunxue Bai Harry J de Koning A Uraujh Yousaf-Khan Annette McWilliams Ming Sound Tsao Prasad S Adusumilli Ramón Rami-Porta Hisao Asamura Paul E Van Schil Gail E Darling Suresh S Ramalingam Daniel R Gomez Kenneth E Rosenzweig Stefan Zimmermann Solange Peters Sai-Hong Ignatius Ou Thanyanan Reungwetwattana Pasi A Jänne Tony S Mok Heather A Wakelee Robert Pirker Julien Mazières Julie R Brahmer Yang Zhou Roy S Herbst Vassiliki A Papadimitrakopoulou Mary W Redman Murry W Wynes David R Gandara Ronan J Kelly Fred R Hirsch Harvey I Pass

J Thorac Oncol 2016 05 22;11(5):613-638. Epub 2016 Mar 22.

Department of Cardiothoracic Surgery, New York University Langone Medical Center, New York, New York.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2016.03.012DOI Listing
May 2016

Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007).

Authors:
Sai-Hong Ignatius Ou Yiyun Tang Anna Polli Keith D Wilner Patrick Schnell

Cancer Med 2016 Apr 28;5(4):617-22. Epub 2016 Jan 28.

Pfizer Oncology, New York City, New York.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cam4.622DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831279PMC
April 2016

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

Authors:
Sai-Hong Ignatius Ou Jin Seok Ahn Luigi De Petris Ramaswamy Govindan James Chih-Hsin Yang Brett Hughes Hervé Lena Denis Moro-Sibilot Alessandra Bearz Santiago Viteri Ramirez Tarek Mekhail Alexander Spira Walter Bordogna Bogdana Balas Peter N Morcos Annabelle Monnet Ali Zeaiter Dong-Wan Kim

J Clin Oncol 2016 Mar 23;34(7):661-8. Epub 2015 Nov 23.

Sai-Hong Ignatius Ou, University of California Irvine School of Medicine, Orange, CA; Jin Seok Ahn, Sungkyunkwan University School of Medicine; Luigi De Petris, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden; Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; James Chih-Hsin Yang, National Taiwan University, Taipei, Taiwan; Brett Hughes, The Prince Charles Hospital, Chermside, and University of Queensland, Queensland, Australia; Hervé Lena, Centre Hospitalier Universitaire de Rennes, Rennes; Denis Moro-Sibilot, Centre Hospitalier Universitaire de Grenoble, Institut National de la Santé et de la Recherche Médicale U823, Grenoble, France; Alessandra Bearz, National Cancer Institute, Aviano, Italy; Santiago Viteri Ramirez, Quiron-Dexeus University Hospital, Barcelona, Spain; Tarek Mekhail, Florida Hospital Cancer Institute, Orlando, FL; Alexander Spira, Virginia Cancer Specialists, Fairfax, VA; and Walter Bordogna, Bogdana Balas, Peter N. Morcos, Annabelle Monnet, and Ali Zeaiter, F. Hoffmann-La Roche, Basel, Switzerland; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/jco.2015.63.9443DOI Listing
March 2016

Laying the Groundwork to Confront the Final Frontier of CNS Metastasis in NSCLC with Targetable Driver Mutations.

Authors:
Thanyanan Reungwetwattana Sai-Hong Ignatius Ou

J Thorac Oncol 2016 Mar;11(3):281-3

Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, California. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2016.01.005DOI Listing
March 2016

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.

Authors:
Tianhong Li Patricia LoRusso Michael L Maitland Sai-Hong Ignatius Ou Erkut Bahceci Howard A Ball Jung Wook Park Geoffrey Yuen Anthony Tolcher

J Hematol Oncol 2016 Mar 10;9:23. Epub 2016 Mar 10.

South Texas Accelerated Research Therapies (START) Center for Cancer Care, San Antonio, TX, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1186/s13045-016-0254-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786998PMC
March 2016

Identification of BRAF Kinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy.

Authors:
Samuel J Klempner Rodolfo Bordoni Kyle Gowen Henry Kaplan Philip J Stephens Sai-Hong Ignatius Ou Siraj M Ali

JAMA Oncol 2016 Feb;2(2):272-4

Foundation Medicine Inc, Cambridge, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1001/jamaoncol.2015.4437DOI Listing
February 2016

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Authors:
Alice T Shaw Leena Gandhi Shirish Gadgeel Gregory J Riely Jeremy Cetnar Howard West D Ross Camidge Mark A Socinski Alberto Chiappori Tarek Mekhail Bo H Chao Hossein Borghaei Kathryn A Gold Ali Zeaiter Walter Bordogna Bogdana Balas Oscar Puig Volkmar Henschel Sai-Hong Ignatius Ou

Lancet Oncol 2016 Feb 19;17(2):234-242. Epub 2015 Dec 19.

Chao Family Comprehensive Cancer Center, University of California, Irvine School of Medicine, Orange, CA, USA.

View Article

Download full-text PDF

 Source
http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S147020451500488
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(15)00488-XDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752892PMC
February 2016

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.

Authors:
Sandeep Kodityal Julia A Elvin Rachel Squillace Nikita Agarwal Vincent A Miller Siraj M Ali Samuel J Klempner Sai-Hong Ignatius Ou

Lung Cancer 2016 Feb 3;92:19-21. Epub 2015 Dec 3.

Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2015.11.023DOI Listing
February 2016

MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval.

Authors:
Thanyanan Reungwetwattana Sai-Hong Ignatius Ou

Transl Lung Cancer Res 2015 Dec;4(6):820-4

1 Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, 270 Rama 6 Road, Tungpayathai, Ratchathewee, Bangkok 10400, Thailand ; 2 Division of Hematology Oncology, Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.12.03DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700217PMC
December 2015

Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.

Authors:
Benjamin P Levy Marc D Chioda Dana Herndon John W Longshore Mohamed Mohamed Sai-Hong Ignatius Ou Craig Reynolds Jaspal Singh Ignacio I Wistuba Paul A Bunn Fred R Hirsch

Oncologist 2015 Oct 1;20(10):1175-81. Epub 2015 Sep 1.

Mount Sinai Health Systems, New York, New York, USA; Pfizer Oncology, New York, New York, USA; Cone Health Cancer Center, Greensboro, North Carolina, USA; Carolinas Pathology Group, Carolinas HealthCare System, Charlotte, North Carolina, USA; Chao Family Comprehensive Cancer Center, University of California at Irvine School of Medicine, Orange, California, USA; US Oncology Research, Ocala, Florida, USA; Carolinas HealthCare System, Charlotte, North Carolina, USA; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; University of Colorado Cancer Center, Aurora, Colorado, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1634/theoncologist.2015-0114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591939PMC
October 2015

Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning.

Authors:
Samuel J Klempner Alexander Raufi Sai-Hong Ignatius Ou

Transl Lung Cancer Res 2015 Oct;4(5):649-52

1 Department of Medicine, Division of Hematology-Oncology, 2 Department of Medicine, University of California Irvine School of Medicine, Orange, CA 92868, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.07.03DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630509PMC
October 2015

The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review.

Authors:
Samuel J Klempner Sai-Hong Ignatius Ou Daniel B Costa Paul A VanderLaan Eric M Sanford Alexa Schrock Laurie Gay Siraj M Ali Vincent A Miller

Clin Lung Cancer 2015 Sep 26;16(5):334-339.e1. Epub 2015 Mar 26.

Foundation Medicine Inc, Cambridge, MA.

View Article

Download full-text PDF

 Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304150007
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2015.03.004DOI Listing
September 2015

Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening.

Authors:
Jeeyun Lee Hee Cheol Kim Jung Yong Hong Kai Wang Sun Young Kim Jiryeon Jang Seung Tae Kim Joon Oh Park Ho Yeong Lim Won Ki Kang Young Suk Park Jiyun Lee Woo Yong Lee Yoon Ah Park Jung Wook Huh Seong Hyeon Yun In-Gu Do Seok Hyung Kim Sohail Balasubramanian Philip J Stephens Jeffrey S Ross Gang Gary Li Zachary Hornby Siraj M Ali Vincent A Miller Kyoung-Mee Kim Sai-Hong Ignatius Ou

Oncotarget 2015 Sep;6(27):24320-32

Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.18632/oncotarget.4462DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695188PMC
September 2015

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.

Authors:
Samuel J Klempner Lyudmila A Bazhenova Fadi S Braiteh Petros G Nikolinakos Kyle Gowen Claudia M Cervantes Juliann Chmielecki Joel R Greenbowe Jeffrey S Ross Philip J Stephens Vincent A Miller Siraj M Ali Sai-Hong Ignatius Ou

Lung Cancer 2015 Sep 29;89(3):357-9. Epub 2015 Jun 29.

Division of Hematology-Oncology, Department of Medicine, Chao Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2015.06.021DOI Listing
September 2015

Gastrointestinal malignancies harbor actionable MET exon 14 deletions.

Authors:
Jeeyun Lee Sai-Hong Ignatius Ou Ji Min Lee Hee Cheol Kim Mineui Hong Sun Young Kim Jiryeon Jang Soomin Ahn So Young Kang Sujin Lee Seung Tae Kim Bogyou Kim Jaehyun Choi Kyung-Ah Kim Jiyun Lee Charny Park Se Hoon Park Joon Oh Park Ho Yeong Lim Won Ki Kang Keunchil Park Young Suk Park Kyoung-Mee Kim

Oncotarget 2015 Sep;6(29):28211-22

Innovative Cancer Medicine Institute, Samsung Medical Center, Seoul, Republic of Korea.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.18632/oncotarget.4721DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695055PMC
September 2015

Darkness before dawn, but will the sun always rise?

Authors:
Sai-Hong Ignatius Ou

Cancer 2015 Aug 17;121(15):2514-6. Epub 2015 Apr 17.

Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.29388DOI Listing
August 2015

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Authors:
Garrett M Frampton Siraj M Ali Mark Rosenzweig Juliann Chmielecki Xinyuan Lu Todd M Bauer Mikhail Akimov Jose A Bufill Carrie Lee David Jentz Rick Hoover Sai-Hong Ignatius Ou Ravi Salgia Tim Brennan Zachary R Chalmers Savina Jaeger Alan Huang Julia A Elvin Rachel Erlich Alex Fichtenholtz Kyle A Gowen Joel Greenbowe Adrienne Johnson Depinder Khaira Caitlin McMahon Eric M Sanford Steven Roels Jared White Joel Greshock Robert Schlegel Doron Lipson Roman Yelensky Deborah Morosini Jeffrey S Ross Eric Collisson Malte Peters Philip J Stephens Vincent A Miller

Cancer Discov 2015 Aug 13;5(8):850-9. Epub 2015 May 13.

Foundation Medicine Inc., Cambridge, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/2159-8290.CD-15-0285DOI Listing
August 2015

Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling.

Authors:
Sai-Hong Ignatius Ou Zachary R Chalmers Michele C Azada Jeffrey S Ross Philip J Stephens Siraj M Ali Vincent A Miller

Lung Cancer 2015 Jun 21;88(3):352-4. Epub 2015 Mar 21.

Foundation Medicine, Inc., 150 Second Street, Cambridge, MA 02141, United States.

View Article

Download full-text PDF

 Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002150016
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2015.03.014DOI Listing
June 2015

Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management.

Authors:
Sai-Hong Ignatius Ou Samuel J Klempner Michele C Azada Veronica Rausei-Mills Christopher Duma

Lung Cancer 2015 Jun 30;88(3):355-9. Epub 2015 Mar 30.

Hoag Neurosciences Institute, Director, Hoag Brain Tumor Program, Hoag Memorial Hospital Presbyterian, Newport Beach, CA 92663, United States.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2015.03.022DOI Listing
June 2015

Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.

Authors:
Samuel J Klempner Sai-Hong Ignatius Ou

Chin Clin Oncol 2015 Jun;4(2):20

Department of Medicine, Division of Hematology-Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA 92868, USA.

View Article

Download full-text PDF

 Source
http://www.thecco.net/article/view/6520/7543
Publisher Site
http://dx.doi.org/10.3978/j.issn.2304-3865.2015.05.03DOI Listing
June 2015

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.

Authors:
Sai-Hong Ignatius Ou Joel Greenbowe Ziad U Khan Michele C Azada Jeffrey S Ross Phil J Stevens Siraj M Ali Vincent A Miller Barbara Gitlitz

Lung Cancer 2015 May 12;88(2):231-4. Epub 2015 Feb 12.

USC Norris Comprehensive Cancer Center and Hospital, Department of Medicine, Division of Medical Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, United States.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2015.02.005DOI Listing
May 2015

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.

Authors:
Siraj M Ali Eric M Sanford Samuel J Klempner Douglas A Rubinson Kai Wang Norma A Palma Juliann Chmielecki Roman Yelensky Gary A Palmer Deborah Morosini Doron Lipson Daniel V Catenacci Fadi Braiteh Rachel Erlich Philip J Stephens Jeffrey S Ross Sai-Hong Ignatius Ou Vincent A Miller

Oncologist 2015 May 16;20(5):499-507. Epub 2015 Apr 16.

Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University of Chicago, Chicago, Illinois, USA; Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA; Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1634/theoncologist.2014-0378DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425384PMC
May 2015

The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.

Authors:
Yoshikazu Hasegawa Masahiko Ando Makoto Maemondo Satomi Yamamoto Shun-Ichi Isa Hideo Saka Akihito Kubo Tomoya Kawaguchi Minoru Takada Rafael Rosell Takayasu Kurata Sai-Hong Ignatius Ou

Oncologist 2015 Mar 5;20(3):307-15. Epub 2015 Feb 5.

Izumi Municipal Hospital, Osaka, Japan; Nagoya University Hospital, Nagoya, Aichi, Japan; Miyagi Cancer Center, Miyagi, Japan; University of Kansas Cancer Center, Kansas City, Kansas, USA; National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan; National Hospital Organization Nagoya Medical Center, Aichi, Japan; Aichi Medical University School of Medicine, Nagoya, Aichi, Japan; Graduate School of Medicine, Osaka City University, Osaka, Japan; Koyo Hospital, Wakayama, Japan; Catalan Institute of Oncology, Barcelona, Spain; Kansai Medical University Hirakata Hospital, Osaka, Japan; Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California, USA

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1634/theoncologist.2014-0285DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350797PMC
March 2015

Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.

Authors:
Stephanie Lu Michele C Azada Sai-Hong Ignatius Ou

Lung Cancer 2015 Feb 19;87(2):207-9. Epub 2014 Dec 19.

Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, United States; Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, CA 92868, United States. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2014.12.011DOI Listing
February 2015

Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.

Authors:
Sai-Hong Ignatius Ou Karen R Sommers Michele C Azada Edward B Garon

Oncologist 2015 Feb 7;20(2):224-6. Epub 2015 Jan 7.

Jonsson Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles School of Medicine, Los Angeles, California, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1634/theoncologist.2014-0309DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319629PMC
February 2015

SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).

Authors:
Sai-Hong Ignatius Ou James Moon Linda L Garland Philip C Mack Joseph R Testa Anne S Tsao Antoniette J Wozniak David R Gandara

J Thorac Oncol 2015 Feb;10(2):387-91

*Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; †SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; ‡Department of Medicine, Arizona Cancer Center, University of Arizona Tucson School of Medicine, Tucson, AZ; §Department of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA; ║Fox Chase Cancer Center, Philadelphia, PA; ¶Department of Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and #Department of Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/JTO.0000000000000360DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304604PMC
February 2015

Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.

Authors:
Sai-Hong Ignatius Ou Samuel J Klempner Joel R Greenbowe Michele Azada Alexa B Schrock Siraj M Ali Jeffrey S Ross Philip J Stephens Vincent A Miller

J Thorac Oncol 2014 Dec;9(12):1821-5

*Division of Hematology-Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California; †Foundation Medicine, Inc., Cambridge, Massachusetts; and ‡Departmente of Pathology and Laboratory Medicine, Albany Medical Center, Albany, New York.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/JTO.0000000000000368DOI Listing
December 2014

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.

Authors:
Rafael Rosell Niki Karachaliou Juergen Wolf Sai-Hong Ignatius Ou

Lancet Respir Med 2014 Dec 19;2(12):966-8. Epub 2014 Nov 19.

Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology/Oncology; University of California Irvine School of Medicine, CA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/S2213-2600(14)70259-0DOI Listing
December 2014

Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment.

Authors:
Samuel J Klempner Golnaz Aubin Atreya Dash Sai-Hong Ignatius Ou

Oncologist 2014 Sep 5;19(9):1008-10. Epub 2014 Aug 5.

Chao Family Comprehensive Cancer Center and Division of Hematology Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1634/theoncologist.2014-0216DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153456PMC
September 2014

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Authors:
Shirish M Gadgeel Leena Gandhi Gregory J Riely Alberto A Chiappori Howard L West Michele C Azada Peter N Morcos Ruey-Min Lee Linta Garcia Li Yu Frederic Boisserie Laura Di Laurenzio Sophie Golding Jotaro Sato Shumpei Yokoyama Tomohiro Tanaka Sai-Hong Ignatius Ou

Lancet Oncol 2014 Sep 18;15(10):1119-28. Epub 2014 Aug 18.

Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA USA. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/S1470-2045(14)70362-6DOI Listing
September 2014

To the editor.

Authors:
Sai-Hong Ignatius Ou

J Thorac Oncol 2014 Jul;9(7):e57-8

Medicine-Hematology-Oncology, Chao Family Comprehensive Cancer Center, Irvine, CA.

View Article

Download full-text PDF

 Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153034
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000192DOI Listing
July 2014

Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?

Authors:
Sai-Hong Ignatius Ou Ross A Soo Akihito Kubo Tomoya Kawaguchi Myung-Ju Ahn

Front Oncol 2014 1;4:58. Epub 2014 Apr 1.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , South Korea.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.3389/fonc.2014.00058DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978317PMC
June 2014